Trial-Results center  
Clinical trial results database in Heart and vessels Feedback    Home


Related trials

ACCELERATE, 2015 - evacetrapib vs placebo

IMPROVE-IT, 2014 - ezetimibe vs control

dal-OUTCOMES, 2012 - dalcetrapib vs placebo

dal-VESSEL, 2011 - dalcetrapib vs placebo

AIM-HIGH, 2011 - niacin vs placebo (on top statin)

SHARP, 2010 - ezetimibe+simvastatin vs placebo

ARBITER-HALTS 6, 2010 - ezetimibe vs niacin

SEARCH, 2010 - simvastatin high dose vs simvastatin

ACCORD lipid, 2010 - fenofibrate vs placebo (on top simvastatine)

ACCORD lipid (subgroup Eye study), 2010 - fenofibrate vs placebo (on top simvastatine)

DEFINE, 2010 - anacetrapib vs placebo

ARBITER 6-HALTS (niacin vs ezetimibe), 2009 - niacin vs ezetimibe

ARBITER 2, 2009 - niacin vs placebo (on top statin)

Emmerich, 2009 - etofibrate vs placebo

Oxford Niaspan Study, 2009 - niacin vs placebo (on top statin)

JUPITER, 2008 - rosuvastatin vs placebo

SANDS, 2008 - aggressive treatment vs standard teatment

Tuttle, 2008 - low fat diet vs mediterranean-style diet

GISSI-HF rosuvastatine, 2008 - rosuvastatin vs placebo

ILLUSTRATE, 2007 - torcetrapib vs placebo (on top of atorvastatin)

SAGE, 2007 - atorvastatin high dose vs pravastatin

Krum, 2007 - rosuvastatin vs placebo

RADIANCE 2, 2007 - torcetrapib vs placebo (on top of atorvastatin)

ILLUMINATE, 2007 - torcetrapib vs placebo (on top of atorvastatin)

CORONA, 2007 - rosuvastatin vs placebo



See also:

  • All cardiovascular prevention clinical trials
  • All clinical trials of HDL increasing drugs
  • All clinical trials of etofibrate
  •  
     Emmerich study, 2009 TRC10782 
    download pdf: etofibrate | cholesterol lowering intervention for cardiovascular prevention

    Treatments

    Studied treatment etofibrate 1g/j
    Control treatment placebo

    Patients

    Patients patients with type 2 diabetes mellitus and concomitant diabetic retinopathy
    Baseline characteristics
    Age (mean), yrs 59 
    Women (%) 69% 
    Total cholesterol (mmol/l) NA 
    Diabetes(%) 100% 

    Method and design

    Randomized effectives NA / NA (studied vs. control)
    Design Parallel groups
    Blinding double-blind
    Follow-up duration 12 months
    Geographic area Germany
    Primary endpoint not defined


    Results

    No results available for this trial - no clinical endpoint reported

    Meta-analysis of all similar trials:

    cholesterol lowering intervention in cardiovascular prevention for diabetic patients

    cholesterol lowering intervention in cardiovascular prevention for all chronical situations

    HDL increasing drugs in cardiovascular prevention for all type of patients



    Reference(s)

    TrialResults-center ID TRC10782
    Trials register # NA
    • Emmerich KH, Poritis N, Stelmane I, Klindzane M, Erbler H, Goldsteine J, Görtelmeyer R. [Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy]. Klin Monbl Augenheilkd 2009;226:561-7 - 10.1055/s-0028-1109516
      Pubmed | Hubmed | Fulltext

    (c) 2004-2016 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend

    100Heart and vessels